Clinical Trials Logo

Polycythemia Secondary clinical trials

View clinical trials related to Polycythemia Secondary.

Filter by:
  • None
  • Page 1

NCT ID: NCT06421025 Not yet recruiting - Clinical trials for Polycythemia Secondary

Blood Viscosity in Polycythemia Patients

POLYVISCO
Start date: May 30, 2024
Phase:
Study type: Observational

Polycythemia (PG) corresponds to an increase in erythrocyte parameters on a blood test. A distinction is usually made between primary and secondary PG. The most common primary PG is Vaquez's disease, a hematological cancer. In Vaquez disease, an increase in hematocrit has been reported to be associated with a logarithmic increase in blood viscosity. The main complications of primary PGs (especially in Vaquez disease) are thromboembolic complications. In contrast, thromboembolic complications are rarer in secondary PG. In Vaquez disease, a hematocrit ≤ 45% has been defined as the therapeutic goal for significantly reducing thromboembolic risk. However, this has not been established for secondary PGs. All in all, the definition of the 45% threshold is based solely on clinical studies with no obvious biological argument. What's more, simply lowering blood mass through cytoreduction alone does not appear to be sufficient to significantly reduce thromboembolic risk. To investigator knowledge, there are no studies prospectively evaluating blood viscosity, its determinants and coagulation in different types of polycythemia. Nor are there any data on the direct effect on blood viscosity of the various treatments usually offered.

NCT ID: NCT03624335 Completed - Clinical trials for Hyperbilirubinemia, Neonatal

Influence of Umbilical Cord Clamping Time in the Newborn

Start date: March 23, 2015
Phase: N/A
Study type: Interventional

This study compares two umbilical cord clamping times; the early one, up to a minute (ECC) and the late or delayed one, when the cord stop beating (DCC). The additional blood volume delivered to the newborn from the placenta - placental transference - by delaying umbilical cord ligation, increases the contribution of neonatal iron with increased iron stores in the infant, without increasing neonatal morbidity.